Ascendis Pharma A/S (BVMF:A1SN34)

Market Cap	64.46B
Revenue (ttm)	4.04B
Net Income (ttm)	-1.46B
Shares Out	n/a
EPS (ttm)	-24.18
PE Ratio	n/a
Forward PE	71.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Average Volume	235
Open	70.21
Previous Close	n/a
Day's Range	70.21 - 70.21
52-Week Range	48.60 - 76.48
Beta	0.45
RSI	55.70
Earnings Date	Nov 4, 2025

About Ascendis Pharma

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 1,017
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A1SN34

Financial Performance

In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.

Financial numbers in EUR